Details for New Drug Application (NDA): 016990
✉ Email this page to a colleague
The generic ingredient in INTAL is cromolyn sodium. There are ten drug master file entries for this compound. Eighteen suppliers are listed for this compound. Additional details are available on the cromolyn sodium profile page.
Summary for 016990
Tradename: | INTAL |
Applicant: | Sanofi Aventis Us |
Ingredient: | cromolyn sodium |
Patents: | 0 |
Medical Subject Heading (MeSH) Categories for 016990
Profile for product number 001
Active Rx/OTC/Discontinued: | DISCN | Dosage: | CAPSULE;INHALATION | Strength | 20MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** | ||||
Approval Date: | Approved Prior to Jan 1, 1982 | TE: | RLD: | Yes |
Expired US Patents for NDA 016990
Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
---|---|---|---|---|---|---|---|
Sanofi Aventis Us | INTAL | cromolyn sodium | CAPSULE;INHALATION | 016990-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | INTAL | cromolyn sodium | CAPSULE;INHALATION | 016990-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
Sanofi Aventis Us | INTAL | cromolyn sodium | CAPSULE;INHALATION | 016990-001 | Approved Prior to Jan 1, 1982 | ⤷ Sign Up | ⤷ Sign Up |
>Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Complete Access Available with Subscription